Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers.

Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers.

Histopathology. 2018 Feb 10;:

Authors: Almangush A, Heikkinen I, Bakhti N, Mäkinen LK, Kauppila JH, Pukkila M, Hagström J, Laranne J, Soini Y, Kowalski LP, Grénman R, Haglund C, Mäkitie AA, Coletta RD, Leivo I, Salo T

Abstract
AIMS: Oral tongue squamous cell carcinoma (OTSCC) has a relatively poor outcome and there is a need to identify better prognostic factors. Recently, tumour-stroma ratio (TSR) has been associated with prognosis in several cancers. This multi-institutional study evaluates the prognostic value of TSR from original HE-stained tumor-resection slides in a series of early-stage (cT1-2N0) OTSCC patients.
METHODS AND RESULTS: A TSR cutoff value of 50% was used to divide the patients into stroma-rich (≥50%) and stroma-poor (<50%) groups. The relationships between TSR and clinicopathologic characteristics of 311 early-stage OTSCC cases were analyzed. The prognostic value of TSR in OTSCC was calculated separately and in combination with a previously published cancer cell budding and depth of invasion (BD) prognostic model. A total of 89 cases (28.6%) belonged to the stroma-rich group. In a multivariate analysis, the stroma-rich group had worse disease-free survival with a hazard ratio (HR) of 1.81 (95%CI 1.17-2.79, P= 0.008) and higher cancer-related mortality (HR 1.71, 95%CI 1.02-2.86, P= 0.03). The combination of the highest risk parameter scores of the TSR and the BD model showed a significant correlation with recurrence rate (HR 3.42, 95%CI 1.71-6.82, P= 0.004) and cancer-related mortality (HR 11.63, 95%CI 3.83-35.31, P< 0.001).
CONCLUSIONS: We conclude that TSR is a simple histopathologic feature useful for prognostication of early-stage OTSCC, and suggest that TSR analyses in association with BD score could be included in routine clinical pathology reports for HE-stained slides. This article is protected by copyright. All rights reserved.

PMID: 29427291 [PubMed - as supplied by publisher]

http://ift.tt/2G6oMIn